Inhibitors | Comment | Organism | Structure |
---|---|---|---|
2'-fucosyllactose | - |
Homo sapiens | |
Galbeta(1,3)GalNAc | - |
Homo sapiens | |
Galbeta(1,4)(3-deoxy)GlcNAcbetaOallyl | IC50: 710 mM | Homo sapiens | |
Galbeta(1,4)deoxynojirimycin | IC50: 8 mM | Homo sapiens | |
GDP | 0.05 mM | Homo sapiens | |
GDP-Man | IC50: 2 mM | Homo sapiens |
KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
0.012 | - |
Galbeta(1,4)(5-thioGlc) | - |
Homo sapiens | |
0.016 | - |
Galbeta(1,4)GlcNAcbetaOallyl | - |
Homo sapiens | |
0.034 | - |
Galbeta(1,4)Glucal | - |
Homo sapiens | |
0.035 | - |
Galbeta(1,4)GlcNAc | - |
Homo sapiens | |
0.064 | - |
NeuAcalpha(2,3)Galbeta(1,4)Glucal | - |
Homo sapiens | |
0.07 | - |
NeuAcalpha(2,6)Galbeta(1,4)GlcNAc | - |
Homo sapiens | |
0.1 | - |
NeuAcalpha(2,3)Galbeta(1,4)GlcNAc | - |
Homo sapiens | |
0.28 | - |
NeuAcalpha(2,3)Galbeta(1,4)GlcNAc | - |
Homo sapiens | |
0.4 | - |
Galbeta(1,4)GlcNAcbeta(1,2)Man | - |
Homo sapiens | |
0.5 | - |
Galbeta(1,4)Glc | - |
Homo sapiens | |
0.6 | - |
Galbeta(1,3)GlcNAc | - |
Homo sapiens | |
0.8 | - |
Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc | - |
Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
milk | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
GDP-beta-L-fucose + NeuAcalpha(2,6)Galbeta(1,4)GlcNAc | - |
Homo sapiens | ? | - |
? | |
GDP-L-fucose + 2'-fucosyllactose | - |
Homo sapiens | GDP + ? | - |
? | |
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc | - |
Homo sapiens | GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc | - |
? | |
GDP-L-fucose + Galbeta(1,3)GlcNAc | 130% of the activity with Galbeta(1,4)GlcNAc | Homo sapiens | GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc | - |
? | |
GDP-L-fucose + Galbeta(1,4)-(5-thioGlc) | 51% of the activity with Galbeta(1,4)GlcNAc | Homo sapiens | GDP + ? | - |
? | |
GDP-L-fucose + Galbeta(1,4)Glc | - |
Homo sapiens | GDP + Galbeta(1,4)(Fucalpha(1,3))Glc | - |
? | |
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man | - |
Homo sapiens | GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man | - |
? | |
GDP-L-fucose + Galbeta(1,4)GlcNAcbetaOallyl | 64% of the activity with Galbeta(1,4)GlcNAc | Homo sapiens | GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbetaOallyl | - |
? | |
GDP-L-fucose + Galbeta(1,4)Glucal | 10% of the activity with Galbeta(1,4)GlcNAc | Homo sapiens | GDP + Galbeta(1,4)(Fucalpha(1,3))Glucal | - |
? | |
GDP-L-fucose + NeuAc(2,3)Galbeta(1,4)Glucal | 330% of the activity with Galbeta(1,4)GlcNAc | Homo sapiens | GDP + NeuAc(2,3)Galbeta(1,4)(Fucalpha(1,3))Glucal | - |
? | |
GDP-L-fucose + NeuAc(2,6)Galbeta(1,4)GlcNAc | 13% of the activity with Galbeta(1,4)GlcNAc | Homo sapiens | GDP + NeuAc(2,6)Galbeta(1,4)(Fucalpha(1,3))GlcNAc | - |
? | |
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAc | 620% of the activity with Galbeta(1,4)GlcNAc | Homo sapiens | GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAc | - |
? | |
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbetaOallyl | 380% of the activity with Galbeta(1,4)GlcNAc | Homo sapiens | GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbetaOallyl | - |
? |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
2 | - |
IC50: 2 mM | Homo sapiens | GDP-Man | |
8 | - |
IC50: 8 mM | Homo sapiens | Galbeta(1,4)deoxynojirimycin | |
710 | - |
IC50: 710 mM | Homo sapiens | Galbeta(1,4)(3-deoxy)GlcNAcbetaOallyl |